Inspra

Active Ingredient:: Eplerenone
Origin:: EU

Inspra (Eplerenone)

Q: What is Inspra used for?

Inspra contains eplerenone, an aldosterone antagonist prescribed to lower high blood pressure and to improve outcomes in patients with heart failure, especially after a myocardial infarction.

Q: How does eplerenone work?

Eplerenone blocks mineralocorticoid receptors in the kidney, reducing sodium reabsorption and potassium loss. This leads to increased urine output, lower blood volume, decreased blood pressure, and less cardiac remodeling in heart failure.

Q: What is the usual dose of Inspra?

The dose of Inspra is individualized by the prescribing clinician based on the patient’s condition, kidney function, and potassium levels. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Q: Is Inspra safe in pregnancy or breastfeeding?

Inspra is classified as Pregnancy Category B, indicating no proven risk in animal studies but limited human data. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, after consulting a healthcare professional.

Q: How do I order Inspra from GNH India?

To order Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does Inspra compare with the main alternative drug or class?

The primary alternative to eplerenone is spironolactone, another aldosterone antagonist. Eplerenone is more selective for the mineralocorticoid receptor, resulting in fewer endocrine side effects such as gynecomastia, while providing comparable blood‑pressure‑lowering and heart‑failure benefits.

Q: How should Inspra be stored and handled?

Inspra tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Q: How is Inspra administered?

Inspra is taken orally as a tablet, usually with or without food, and swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician.

Q: What are the most serious risks to watch for while taking Inspra?

The most serious risks include severe hyperkalemia, acute kidney injury, and rare cases of angioedema or severe allergic reactions. Regular monitoring of serum potassium and renal function helps detect these complications early.

Q: Who should not use Inspra?

Inspra should be avoided in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), uncontrolled hyperkalemia, or known hypersensitivity to eplerenone. It is also contraindicated in individuals taking certain potassium‑sparing medications without careful monitoring.

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral tablet for systemic use. It is indicated for the management of hypertension and for reducing morbidity in patients with heart failure following a myocardial infarction, primarily in adult populations.

GNH India supplies Inspra as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under regulated quality standards. Our supply chain ensures consistent availability and compliance with EU regulatory requirements, supporting healthcare providers in delivering evidence‑based cardiovascular therapy.

Manufacturer / TM Owner

Viatris Aps

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Eplerenone is an aldosterone antagonist used in cardiovascular disease management.
Hypertension: lowers blood pressure by reducing sodium retention.
Heart failure (post‑myocardial infarction): improves survival and reduces hospitalizations.
Chronic heart failure with reduced ejection fraction: decreases cardiac remodeling and symptom burden.

How It Works

Eplerenone selectively blocks the mineralocorticoid (aldosterone) receptor in the distal nephron, inhibiting sodium reabsorption and potassium excretion. This antagonism promotes natriuresis and diuresis, leading to reduced extracellular fluid volume, lower blood pressure, and attenuation of cardiac remodeling processes associated with heart failure.

Side Effects

Adverse reactions may occur with eplerenone therapy.

Common Side Effects

Hyperkalemia
Dizziness
Headache
Diarrhea
Nausea
Fatigue

Serious or Rare Side Effects

Severe hyperkalemia
Acute renal failure
Angioedema
Hepatic dysfunction
Marked hypotension
Severe allergic reactions

Precautions & Warnings

Before initiating therapy, consider the following precautions:

Monitor serum potassium: check baseline and periodic levels.
Assess renal function: evaluate creatinine clearance before and during treatment.
Avoid use in severe renal impairment: contraindicated when eGFR <30 mL/min/1.73 m².
Caution in patients with existing hyperkalemia: adjust dose or discontinue.
Use with care during pregnancy (Category B): discuss risks with a healthcare professional.
Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Eplerenone may interact with several medications.

Major Interactions (Avoid)

Potassium supplements or high‑potassium diets: increase risk of hyperkalemia.
ACE inhibitors or ARBs: additive potassium elevation.
NSAIDs: may impair renal function and raise potassium levels.
Cyclosporine: can markedly increase serum potassium.

Moderate Interactions (Monitor Closely)

Thiazide diuretics: may alter potassium balance.
Digoxin: potassium changes can affect digoxin toxicity.
Lithium: renal effects may increase lithium levels.
Rifampin: may reduce eplerenone plasma concentrations.

Frequently Asked Questions

Inspra contains eplerenone, an aldosterone antagonist prescribed to lower high blood pressure and to improve outcomes in patients with heart failure, especially after a myocardial infarction.

Eplerenone blocks mineralocorticoid receptors in the kidney, reducing sodium reabsorption and potassium loss. This leads to increased urine output, lower blood volume, decreased blood pressure, and less cardiac remodeling in heart failure.

The dose of Inspra is individualized by the prescribing clinician based on the patient’s condition, kidney function, and potassium levels. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Inspra is classified as Pregnancy Category B, indicating no proven risk in animal studies but limited human data. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, after consulting a healthcare professional.

To order Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

The primary alternative to eplerenone is spironolactone, another aldosterone antagonist. Eplerenone is more selective for the mineralocorticoid receptor, resulting in fewer endocrine side effects such as gynecomastia, while providing comparable blood‑pressure‑lowering and heart‑failure benefits.

Inspra tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Inspra is taken orally as a tablet, usually with or without food, and swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician.

The most serious risks include severe hyperkalemia, acute kidney injury, and rare cases of angioedema or severe allergic reactions. Regular monitoring of serum potassium and renal function helps detect these complications early.

Inspra should be avoided in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), uncontrolled hyperkalemia, or known hypersensitivity to eplerenone. It is also contraindicated in individuals taking certain potassium‑sparing medications without careful monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.